

COPD inhaled medication table update

This is a 2024 update to the BC Provincial Academic Detailing (PAD) Service's 2020 Table "COPD Inhaled Medications Table" which includes additions to the inhaled medications list and COPD BC PharmaCare coverage changes. Refer to changes. Refer to <a href="https://creativecommons.org/reference-obstructive-pulmonary disease (COPD) for complete details on the state of the sta

Medication	Brand name, inhaler device (dose per inhalation)	Usual adult dose	Cost per 30 days	BC PharmaCare coverage
SABA short-acting beta ₂ agonist			· -	
salbutamol	Ventolin HFA <i>MDI</i> , Airomir <i>MDI</i> , generics (100 mcg)	1-2 inh QID (max 8 inh/day)	\$10/200 inh	regular benefit
	Ventolin <i>Diskus</i> (200 mcg)	1 inh every 4-6 hours (max 4 inh/day)	\$15/60 inh	non-benefit
erbutaline	Bricanyl <i>Turbuhaler</i> (500 mcg)	1-2 inh PRN (max 6 inh/day)	\$15/120 inh	regular benefit
SAMA short-acting muscarinic a	ntagonist			
pratropium	Atrovent HFA MDI (20 mcg)	2-4 inh TID-QID (max 12 inh/day)	\$25/200 inh	regular benefit
SAMA + SABA short-acting muse	carinic antagonist + short-acting beta ₂	agonist		
pratropium + salbutamol	Combivent Respimat (20/100 mcg)	1 inh QID (max 6 inh/day)	\$35/120 inh	regular benefit
AMA long-acting muscarinic ar	tagonist			
umeclidinium	Incruse Ellipta (62.5 mcg)	1 inh once a day	\$55	regular benefit
tiotropium	Spiriva Respimat (2.5 mcg)	2 inh once a day	\$60	
tiotronium	Spiriva <i>HandiHaler</i> , <i>LupinHaler</i> generic	1 inh once a day	\$45 generic	limited coverage after a minimum one- month trial of each regular benefit LAMA
tiotropium	(18 mcg)	1 iiii once a day	\$60	
aclidinium	Tudorza <i>Genuair</i> (400 mcg)	1 inh BID	\$60	
glycopyrronium	Seebri <i>Breezhaler</i> (50 mcg)	1 inh once a day	\$60	
LABA long-acting beta ₂ agonist				
salmeterol	Serevent <i>Diskus</i> (50 mcg)	1 inh BID	\$80	limited coverage
LAMA + LABA long-acting musca	arinic antagonist + long-acting beta2 ag	onist		
aclidinium + formoterol	Duaklir <i>Genuair</i> (400/12 mcg)	1 inh BID	\$70	limited coverage after a 6-month trial of a LAMA or a LABA
glycopyrronium + indacaterol	Ultibro <i>Breezhaler</i> (50/110 mcg)	1 inh once a day	\$85	
tiotropium + olodaterol	Inspiolto Respimat (2.5/2.5 mcg)	2 inh once a day	\$70	
umeclidinium + vilanterol	Anoro Ellipta (62.5/25 mcg)	1 inh once a day	\$95	
ICS + LABA inhaled corticosteroi	d + long-acting beta ₂ agonist	'	·	
fluticasone propionate + salmeterol	Advair <i>Diskus</i> , generics <i>DPI</i> , Wixela <i>Inhub</i> (250/50 mcg)	1 inh BID	\$55 generic \$130	limited coverage after a 6-month trial of a LAMA or a LABA & frequent exacerbations
	Advair <i>Diskus</i> , generics <i>DPI</i> , Wixela <i>Inhub</i> (500/50 mcg)	1 inh BID	\$80 ^{generic} \$180	
fluticasone furoate + vilanterol	Breo Ellipta (100/25 mcg)	1 inh once a day	\$110	
budesonide + formoterol	Symbicort Turbuhaler (200/6 mcg)	2 inh BID	\$100	non-benefit
	icosteroid + long-acting muscarinic ant	agonist + long-acting beta ₂ agonist	·	
fluticasone furoate + umeclidinium + vilanterol	Trelegy Ellipta (100/62.5/25 mcg)	1 inh once a day	\$150	limited coverage after a 6-month trial of LAMA+LABA or ICS+LABA, & frequent exacerbations
budesonide + glycopyrronium + formoterol	Breztri <i>Aerosphere</i> (182/8.2/5.8 mcg)	2 inh BID	\$140	

 $^{\rm 1}\, \rm Health$ Canada Drug Product Monographs; $^{\rm 2}\, \rm BC$ PAD COPD Newsletter 2017

Cost without mark-up and professional fee calculated from McKesson Canada rounded to nearest \$5 (accessed March 6, 2024)